90 related articles for article (PubMed ID: 19043874)
1. Abacavir controversy continues to brew.
Dalton P
Proj Inf Perspect; 2008 Sep; (46):4-7. PubMed ID: 19043874
[No Abstract] [Full Text] [Related]
2. FDA notifications. Large study suggests heart attack risk from use of abacavir or didanosine.
AIDS Alert; 2008 May; 23(5):58-9. PubMed ID: 18642404
[No Abstract] [Full Text] [Related]
3. Heart attack risk with abacavir and didanosine.
AIDS Patient Care STDS; 2008 Apr; 22(4):346-7. PubMed ID: 18434947
[No Abstract] [Full Text] [Related]
4. FDA notifications. Ongoing safety review of abacavir, possible MI risk.
AIDS Alert; 2011 May; 26(5):58-9. PubMed ID: 21649950
[No Abstract] [Full Text] [Related]
5. Anti-HIV agents. Controversial findings on abacavir and heart attacks.
TreatmentUpdate; 2008 Mar; 20(2):1-5. PubMed ID: 18661643
[No Abstract] [Full Text] [Related]
6. Report from the 15th Retrovirus Conference. Is abacavir therapy associated with MI risk?
Hicks CB
AIDS Clin Care; 2008 Apr; 20(4):29. PubMed ID: 19266668
[No Abstract] [Full Text] [Related]
7. Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy.
Hammond E; McKinnon E; Mallal S; Nolan D
AIDS; 2008 Nov; 22(18):2540-3. PubMed ID: 19005279
[No Abstract] [Full Text] [Related]
8. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
; Sabin CA; Worm SW; Weber R; Reiss P; El-Sadr W; Dabis F; De Wit S; Law M; D'Arminio Monforte A; Friis-Møller N; Kirk O; Pradier C; Weller I; Phillips AN; Lundgren JD
Lancet; 2008 Apr; 371(9622):1417-26. PubMed ID: 18387667
[TBL] [Abstract][Full Text] [Related]
9. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management.
Calza L; Manfredi R; Verucchi G
AIDS; 2010 Mar; 24(6):789-802. PubMed ID: 20224307
[No Abstract] [Full Text] [Related]
10. Abacavir (Ziagen).
Res Initiat Treat Action; 2000 Mar; 6(1):16-7. PubMed ID: 11708178
[No Abstract] [Full Text] [Related]
11. Anti-HIV agents. Abacavir once or twice daily.
TreatmentUpdate; 2005; 17(5):8. PubMed ID: 17219659
[No Abstract] [Full Text] [Related]
12. 1592 (abacavir): do not rechallenge after hypersensitivity reaction.
James JS
AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916
[TBL] [Abstract][Full Text] [Related]
13. Abacavir sulfate and mania in HIV.
Brouilette MJ; Routy JP
Am J Psychiatry; 2007 Jun; 164(6):979-80. PubMed ID: 17541065
[No Abstract] [Full Text] [Related]
14. Anti-HIV agents. Abacavir--as good as AZT?
TreatmentUpdate; 2003 Oct; 15(6):3-4. PubMed ID: 17216861
[No Abstract] [Full Text] [Related]
15. Tolerability of abacavir in the clinical setting.
Martín-Carbonero L; Barreiro P; Soriano V; González-Lahoz J
Clin Microbiol Infect; 2000 Nov; 6(11):621-2. PubMed ID: 11168068
[No Abstract] [Full Text] [Related]
16. Switching to abacavir to reduce fat wasting.
TreatmentUpdate; 2002 Mar; 14(3):4-5. PubMed ID: 12033189
[No Abstract] [Full Text] [Related]
17. Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir.
Kowalska JD; Kirk O; Mocroft A; Høj L; Friis-Møller N; Reiss P; Weller I; Lundgren JD
HIV Med; 2010 Mar; 11(3):200-8. PubMed ID: 19863618
[TBL] [Abstract][Full Text] [Related]
18. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Abacavir and CVD--again.
Sax PE
J Watch AIDS Clin Care; 2009 Oct; 21(10):81. PubMed ID: 20458812
[No Abstract] [Full Text] [Related]
19. Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone.
Moyle GJ
AIDS Read; 2003 Nov; 13(11):528, 533-5. PubMed ID: 14649622
[No Abstract] [Full Text] [Related]
20. Abacavir and the potential risk of myocardial infarction.
Cutrell A; Brothers C; Yeo J; Hernandez J; Lapierre D
Lancet; 2008 Apr; 371(9622):1413. PubMed ID: 18387668
[No Abstract] [Full Text] [Related]
[Next] [New Search]
